An epigenomic approach to therapy for tamoxifen-resistant breast cancer
Shea, Martin J
Creighton, Chad J
Hilsenbeck, Susan G
Osborne, C Kent
O'Malley, Bert WNote: Order does not necessarily reflect citation order of authors.
MetadataShow full item record
CitationFeng, Q., Z. Zhang, M. J. Shea, C. J. Creighton, C. Coarfa, S. G. Hilsenbeck, R. Lanz, et al. 2014. “An epigenomic approach to therapy for tamoxifen-resistant breast cancer.” Cell Research 24 (7): 809-819. doi:10.1038/cr.2014.71. http://dx.doi.org/10.1038/cr.2014.71.
AbstractTamoxifen has been a frontline treatment for estrogen receptor alpha (ERα)-positive breast tumors in premenopausal women. However, resistance to tamoxifen occurs in many patients. ER still plays a critical role in the growth of breast cancer cells with acquired tamoxifen resistance, suggesting that ERα remains a valid target for treatment of tamoxifen-resistant (Tam-R) breast cancer. In an effort to identify novel regulators of ERα signaling, through a small-scale siRNA screen against histone methyl modifiers, we found WHSC1, a histone H3K36 methyltransferase, as a positive regulator of ERα signaling in breast cancer cells. We demonstrated that WHSC1 is recruited to the ERα gene by the BET protein BRD3/4, and facilitates ERα gene expression. The small-molecule BET protein inhibitor JQ1 potently suppressed the classic ERα signaling pathway and the growth of Tam-R breast cancer cells in culture. Using a Tam-R breast cancer xenograft mouse model, we demonstrated in vivo anti-breast cancer activity by JQ1 and a strong long-lasting effect of combination therapy with JQ1 and the ER degrader fulvestrant. Taken together, we provide evidence that the epigenomic proteins BRD3/4 and WHSC1 are essential regulators of estrogen receptor signaling and are novel therapeutic targets for treatment of Tam-R breast cancer.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:12717482
- HMS Scholarly Articles